Have a personal or library account? Click to login
Antimicrobial assesment of aroylhydrazone derivatives in vitro Cover

Antimicrobial assesment of aroylhydrazone derivatives in vitro

Open Access
|Mar 2019

References

  1. 1. Ł. Popiołek, Hydrazide-hydrazones as potential antimicrobial agents: overview of the literature since 2010, Med. Chem. Res. 26 (2017) 287–301; DOI 10.1007/s00044-016-1756-y10.1007/s00044-016-1756-y
  2. 2. M. K. Dahlgren, C. E. Zetterström, Å. Gylfe, A. Linusson and M. Elofsson, Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia, Bioorg. Med. Chem. 18 (2010) 2686–2703; https://doi.org/10.1016/j.bmc.2010.02.02210.1016/j.bmc.2010.02.02220219378
  3. 3. P. V. Bernhardt, P. Chin, P. C. Sharpe and D. R. Richardson, Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity, Dalton Trans. 30 (2007) 3232–3244; https://doi.org/10.1039/b704102k10.1039/b704102k17893768
  4. 4. K. Hruskova, P. Kovarikova, P. Bendova, P. Haskova, E. Mackova, J. Stariat, A. Vavrova, K. Vavrova and T. Simunek, Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis, Chem. Res. Toxicol. 24 (2011) 290–302; https://doi.org/10.1021/tx100359t10.1021/tx100359t21214215
  5. 5. P. Kovaríkova, Z. Mrkvičkova and J. Klimeš, Investigation of the stability of aromatic hydrazones in plasma and related biological material, J. Pharm. Biomed. Anal. 47 (2008) 360–370; https://doi.org/10.1016/j.jpba.2008.01.01110.1016/j.jpba.2008.01.01118294799
  6. 6. N. Galić, A. Dijanošić, D. Kontrec and S. Miljanić, Structural investigation of aroylhydrazones in dimethylsulphoxide/water mixtures, Spectrochim. Acta A95 (2012) 347–353; https://doi.org/10.1016/j.saa.2012.03.08610.1016/j.saa.2012.03.08622542687
  7. 7. C. F. Da Costa, A. C. Pinheiro, M. V. De Almeida, M. C. Lourenço and M. V. De Souza, Synthesis and antitubercular activity of novel amino acid derivatives, Chem. Biol. Drug Des. 79 (2012) 216–222; https://doi.org/10.1111/j.1747-0285.2011.01269.x10.1111/j.1747-0285.2011.01269.x22078007
  8. 8. M. C. Mandewale, B. Thorat, Y. Nivid, R. Jadhav, A. Nagarsekar and R. Yamgar, Synthesis, structural studies and antituberculosis evaluation of new hydrazone derivatives of quinoline and their Zn(II) complexes, J. Saudi Chem. Soc. 22 (2018) 218–228; https://doi.org/10.1016/j.jscs.2016.04.00310.1016/j.jscs.2016.04.003
  9. 9. Y. Ozkay, Y. Tunali, H. Karaca and I. Işikdağ, Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazone moiety, Eur. J. Med. Chem. 45 (2010) 3293–3298; https://doi.org/10.1016/j.ejmech.2010.04.01210.1016/j.ejmech.2010.04.01220451306
  10. 10. T. Benković, A. Kenđel, J. Parlov-Vuković, D. Kontrec, V. Chiş, S. Miljanić and N. Galić, Multiple dynamics of aroylhydrazone induced by mutual effect of solvent and light - spectroscopic and computational study, J. Mol. Liq. 255 (2018) 18–25; https://doi.org/10.1016/j.saa.2017.09.03810.1016/j.saa.2017.09.03828938170
  11. 11. T. Benković, D. Kontrec, V. Tomišić, A. Budimir and N. Galić, Acid-base properties and kinetics of hydrolysis of aroylhydrazones derived from nicotinic acid hydrazide, J. Solution Chem. 45 (2016) 1227–1245; https://doi.org/10.1007/s10953-016-0504-810.1007/s10953-016-0504-8
  12. 12. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), EUCAST Discussion Document E. Dis 5.1, Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution, Clin. Microbiol. Infect. 9 (2003) 1–7; https://doi.org/10.1046/j.1469-0691.2003.00790.x10.1046/j.1469-0691.2003.00790.x
  13. 13. M. C. Arendrup, J. Meletiadis, J. W. Mouton, K. Lagrou, Petr Hamal, J. Guinea, and the Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing, EUCAST Definitive Document E. Def. 7.3.1. January 2017 - Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts; http://www.eucast.org/ast_of_fungi/methodsinantifungalsusceptibilitytesting/susceptibility_testing_of_yeasts/; last access date December 13, 2018.
  14. 14. J. Vlainić, I. Kosalec, K. Pavić, D. Hadjipavlou-Litina, E. Pontiki and B. Zorc, Insights into biological activity of ureidoamides with primaquine and amino acid moieties, J. Enzyme Inhib. Med. Chem. 33 (2018) 376–382; https://doi.org/10.1080/14756366.2017.142306710.1080/14756366.2017.1423067602103529363364
  15. 15. S. Purser, P. R. Moore, S. Swallow and V. Gouverneur, Fluorine in medicinal chemistry, Chem. Soc. Rev. 37 (2008) 320–330;10.1039/B610213C
DOI: https://doi.org/10.2478/acph-2019-0020 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Language: English
Page range: 277 - 285
Accepted on: Dec 14, 2018
Published on: Mar 28, 2019
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:

© 2019 Saša Polović, Vanja Ljoljić Bilić, Ana Budimir, Darko Kontrec, Nives Galić, Ivan Kosalec, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.